Joanne Kim v. Regeneron Pharmaceuticals, Inc. and Ashutosh Katiyar

CourtDistrict Court, S.D. New York
DecidedMarch 25, 2026
Docket1:24-cv-05234
StatusUnknown

This text of Joanne Kim v. Regeneron Pharmaceuticals, Inc. and Ashutosh Katiyar (Joanne Kim v. Regeneron Pharmaceuticals, Inc. and Ashutosh Katiyar) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Joanne Kim v. Regeneron Pharmaceuticals, Inc. and Ashutosh Katiyar, (S.D.N.Y. 2026).

Opinion

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK JOANNE KIM, Plaintiff, No. 1:24-cv-05234 (LAP) -against- OPINION AND ORDER REGENERON PHARMACEUTICALS, INC., and ASHUTOSH KATIYAR Defendants.

LORETTA A. PRESKA, Senior United States District Judge:

Before the Court is Regeneron Pharmaceuticals, Inc. (“Regeneron”) and Ashutosh Katiyar’s (“Katiyar”) (collectively, “Defendants”) joint motion for partial dismissal1 of Plaintiff’s Amended Complaint (see Am. Compl., dated Oct. 7, 2024 [dkt. no. 15]) filed pursuant to Federal Rule of Civil Procedure 12(b)(6). Plaintiff opposes the motion.2 For the reasons set forth below, Defendants’ Motion is GRANTED in part and DENIED in part. I. Background A. Factual Allegations For the purposes of this motion, the Court assumes that the following allegations are true and draws all reasonable inferences

1 (See Memorandum in Support of Motion to Dismiss (“Defendants’ Mem.”), dated Oct. 28, 2024 [dkt. no. 19]; Reply Memorandum for Partial Dismissal (“Defendants’ Reply”), dated Dec. 9, 2024 [dkt. no. 23].) 2 (See Plaintiff’s Opposition to Partial Motion to Dismiss (“Pl. Opp.”), dated Nov. 25, 2024 [dkt. no. 22].) in favor of Plaintiff. See Koch v. Christie's Int'l PLC, 699 F.3d 141, 145 (2d Cir. 2012). As alleged in the Amended Complaint, Plaintiff Joanne Kim (“Plaintiff”) is a woman and the primary caregiver of her disabled child. (Am. Compl. ¶ 14.)3 Plaintiff worked in New York City as the Director of Customer Insights & Analytics (“CIA”) of Regeneron

from June 5, 2020 until her February 9, 2024 termination. (Id.) One of Plaintiff’s responsibilities was to create and lead a new department within CIA called Competitive Intelligence (“CI”). (Id. ¶¶ 19-20.) Plaintiff was successful at her job and regularly received positive performance reviews. (Id. ¶¶ 24-27.) Plaintiff initially reported to the head of the CIA department, Arvind Balasundaram (“Balasundaram”). (Id. ¶ 21.) In August 2022, Regeneron restructured CI such that it no longer operated as a separate group. Instead, all CI employees were reassigned to one of Regeneron’s primary commercial business units. Plaintiff was reassigned to the Eylea group, one of the

company’s most popular brands. (Id. ¶¶ 29-30.) Defendant Katiyar (“Katiyar”) then became head of the Eylea group, making him

3 Due to a drafting error, the paragraph numbers 52-60 and 71-76 appear twice in the Amended Complaint. For the sake of clarity, the Court identifies the section and paragraph numbers for the affected paragraphs. Plaintiff’s direct manager. (Id. ¶ 31.) Plaintiff’s previous manager, Balasundaram, became her dotted line manager.4 (Id.) Plaintiff’s young daughter suffers from a myriad of health conditions and disabilities that require her to attend special schools and receive extraordinary care. (Id. ¶¶ 32-33.) Plaintiff shared these challenges with Balasundaram, who in turn shared the

information with Katiyar when Katiyar became Plaintiff’s manager. (Id. ¶¶ 34-35.) On several occasions, Plaintiff spoke directly to Katiyar about her daughter’s challenges. For example, when Plaintiff had to reschedule or was late to meetings to care for her child, Plaintiff told Katiyar that her daughter’s poor health was the reason for her unavailability. (Id. ¶¶ 36-37.) In March 2023, Plaintiff explained her child’s condition to Dana Jones (“Jones”) in Human Resources (“HR”). (Id. ¶ 40.) Plaintiff asked Jones about the available medical leave options. Despite being qualified for leave under the Family and Medical Leave Act (“FMLA”), Jones did not inform Plaintiff of her rights.

(Id. ¶ 41.) A few months later, in June 2023, Plaintiff broke her hand and required six weeks of recovery time. (Id. ¶ 42.) An unspecified Regeneron employee informed Plaintiff that she was qualified for medical leave under the FMLA. Plaintiff decided to

4 Plaintiff’s complaint does not define the term “dotted line manager.” Accordingly, the Court assumes nothing more than that Balasundaram was one of Plaintiff’s superiors. exercise this right and take six weeks away from work. (Id. ¶ 43.) When Plaintiff informed Katiyar that she would be taking leave, Katiyar complained that Plaintiff was burdening him and made his frustration clear. Katiyar hired two consultants to handle Plaintiff’s work during her absence. (Id. ¶ 45.) Upon Plaintiff’s return, she was met with several instances

of hostile behavior from Katiyar. On one occasion, Katiyar shouted at Plaintiff that her work was useless, which frightened Plaintiff. (Id. ¶ 46.) On another, Katiyar pounded his fists on the table and screamed at Plaintiff again. Katiyar thereafter refused to include Plaintiff in meetings with stakeholders. (Id. ¶ 47.) In September 2023, Plaintiff notified Jones that she would need time off due to a concerning development in her daughter’s health. Plaintiff also explained her child’s health conditions to Jones in greater detail. (Id. ¶ 50.) Jones again neglected to inform Plaintiff of her eligibility to take protected leave under the FMLA. (Id. ¶ 51.) Plaintiff did not further inquire about

the possibility of taking leave because she was concerned about how Katiyar would react given his harsh reaction to her previous time off. (Id. § IV ¶ 52.) In December 2023, Plaintiff contracted COVID for the second time and used two sick days to recover. Katiyar allegedly implied that he believed Plaintiff was lying about contracting COVID again and seemed to be “further enrage[d]” by her use of sick days. (Id. § IV ¶ 53.) On January 24, 2024, Plaintiff asked Katiyar to allow her to return to stakeholder meetings. (Id. § IV ¶ 54.) In response, Katiyar became angry and told Plaintiff she would never be promoted because “it’s all about . . . what perceptions you create to

people.” He then “lectured [Plaintiff] about ‘team dynamics,’ how she ‘collaborate[s] with others,’ and how she ‘behave[s].’” (Id. § IV ¶ 55.) Katiyar also told Plaintiff that her role performed “only a ‘tactical function’ and was ‘just providing some insight back to the business unit [which is] not the role that will get promoted afterwards.’” (Id. § IV ¶ 56.) Katiyar then told Plaintiff that her position “was not going to work for her long term” and would “always . . . make [her] unhappy.” (Id. § IV ¶ 59.) Katiyar’s comments deeply upset Plaintiff. (Id. § IV ¶ 60.) As a result, on January 25, 2024, Plaintiff decided to inform Jones

that one of her superiors was treating her in an abusive and threatening manner and that she was afraid her job would be affected if she made a formal HR complaint. (Id. § V ¶ 53.) Jones told Plaintiff that if the issue was something that could be investigated and resolved in a way that satisfied Plaintiff, that would likely be the best option. (Id. § V ¶ 57.) Jones then told Plaintiff that if she felt her job was no longer the right fit for her, HR could “probably could put together some type of package for [Plaintiff].” (Id. § V ¶ 58.) Plaintiff then revealed Katiyar’s identity and began explaining the specifics of what had occurred, at which point Plaintiff and Jones reached the end of their scheduled call time. (Id. § V ¶¶ 60, 62.) Before the call ended, Plaintiff made it clear that she did not fully explain her

situation. (Id. ¶ 62.) About a week later, on February 1, 2024, Plaintiff met Jones in person to inform Jones that Plaintiff’s child’s medical team recommended that Plaintiff’s child be admitted to a program that required Plaintiff to be available at specific times during the day. (Id.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

McDonnell Douglas Corp. v. Green
411 U.S. 792 (Supreme Court, 1973)
Landgraf v. USI Film Products
511 U.S. 244 (Supreme Court, 1994)
Swierkiewicz v. Sorema N. A.
534 U.S. 506 (Supreme Court, 2002)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
De La Rosa v. Potter
427 F. App'x 28 (Second Circuit, 2011)
Christopher Graham v. Long Island Rail Road
230 F.3d 34 (Second Circuit, 2000)
Joseph v. Treglia v. Town of Manlius
313 F.3d 713 (Second Circuit, 2002)
Koch v. Christie's International PLC
699 F.3d 141 (Second Circuit, 2012)
Rothstein v. UBS AG
708 F.3d 82 (Second Circuit, 2013)

Cite This Page — Counsel Stack

Bluebook (online)
Joanne Kim v. Regeneron Pharmaceuticals, Inc. and Ashutosh Katiyar, Counsel Stack Legal Research, https://law.counselstack.com/opinion/joanne-kim-v-regeneron-pharmaceuticals-inc-and-ashutosh-katiyar-nysd-2026.